Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous microbiome transplant cream
- Development stage
- Unknown
- Lead developer
- MatriSys Bioscience
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
Autologous microbiome transplant cream is a live biotherapeutic intervention developed by the University of California, San Diego (UCSD) for the treatment of atopic dermatitis. The therapy involves isolating a patient's own protective, antimicrobial-producing coagulase-negative Staphylococcus (CoNS-AM+) species, such as *Staphylococcus epidermidis*, from their skin. These bacteria are selectively cultured and then incorporated into a moisturizer for topical reapplication. The mechanism of action relies on the ability of these commensal bacteria to produce antimicrobial peptides that specifically target and reduce the colonization of *Staphylococcus aureus*, thereby restoring a healthy skin microbiome and improving eczema symptoms.
- Other names
- Moisturizer + Antimicrobial BacteriaAutologous Microbiome Transplant
02
Targets
agr (Accessory gene regulator system)Staphylococcus aureus cytoplasmic membrane
Beyond the preview
Go deeper on autologous microbiome transplant cream.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous microbiome transplant cream.